Everything below concerns clinical development. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
== Relations == The attached or orbital margins are connected to the circumference of the orbit by the orbital septum. The lateral angles are attached to the zygomatic bone by the lateral palpebral raphe. The medial angles of the two plates end at the lacrimal lake, and are attached to the frontal process of the maxilla by the medial palpebral ligament). The sulcus subtarsalis is a groove in the inner surface of each eyelid. Along the inner margin of the tarsus are modified sebaceous glands known as tarsal glands (or meibomian glands), aligned vertically within the tarsi: 30 to 40 glands in the upper lid, and 20 to 30 in the lower lid, which secrete a lipid-rich product which helps keep the lacrimal secretions or tears from evaporating too quickly, thus keeping the eye moist.
Sport-Club Freiburg e.V., commonly known as SC Freiburg (German pronunciation: [ʔɛs ˈtseː ˈfʁaɪbʊɐ̯k]), is a German professional football club, based in the city of Freiburg im Breisgau, Baden-Württemberg. It plays in the Bundesliga, having been promoted as champions from the 2. Bundesliga in 2016. Between 1954 and 2021, Freiburg's stadium was the Dreisamstadion; the club moved to the newly built Europa-Park Stadion in 2021.
India was a primary supplier of indigo to Europe as early as the Greco-Roman era. The association of India with indigo is reflected in the Greek word for the dye, indikón (Ἰνδικόν, Indian). The Romans Latinized the term to indicum, which passed into Italian dialect and eventually into English as the word indigo. In Bengal, indigo cultivators revolted against exploitative working conditions created by European merchants and planters in what became known as the Indigo revolt in 1859. The Bengali play Nil Darpan by Indian playwright Dinabandhu Mitra was a fictionalized retelling of the revolt.
Creatinine levels in μmol/L can be converted to mg/dL by dividing them by 88.4. The 32788 number above is equal to 186×88.41.154. A more elaborate version of the MDRD equation also includes serum albumin and blood urea nitrogen (BUN) levels:
Sources: en.wikipedia.org
The habitat of pennyroyal is seasonally damp pasture, where standing water over the winter leaves bare ground in the summer, and where livestock preferentially graze other plants. An analogue of this habitat is found on roadsides, where trampling or disturbance of the ground produces similarly bare soil, particularly where there is waterlogging in winter. It is also found along watercourses, in wet woodland and in abandoned fields. In California, where it is considered an invasive species, it occupies a similar niche, in seeps, streamsides, vernal pools and swales, marshes, and ditches. There is some speculation that it may displace native species in these areas. Few animals eat pennyroyal. In Britain, the only insect known to feed on it is the bug Heterogaster artemisiae Schilling, which is a seed bug that normally feeds on wild thyme. It is considered an axiophyte in many British counties, because low-intensity pasture is a rare habitat, although it has been spreading in recent decades. Its Ellenberg values in Britain are L = 8, F = 7, R = 5, N = 7, and S = 0.
Tryptamines: dimethyltryptamine (DMT) and diethyltryptamine (DET) 4-Hydroxytryptamines: psilocin (4-HO-DMT) and psilocybin (4-PO-DMT) (both found in psilocybin-containing mushrooms) 5-Hydroxytryptamines: bufotenin (5-HO-DMT) 5-Methoxytryptamines: 5-MeO-DMT and 5-MeO-DiPT α-Alkyltryptamines: α-methyltryptamine (AMT) and α-ethyltryptamine (AET; etryptamine) Phenethylamines: Scalines: mescaline (found in peyote) 2Cs: 2C-B, 2C-C, 2C-D, 2C-E, 2C-H, 2C-I, 2C-N, 2C-P, 2C-T-2, 2C-T-4, and 2C-T-7 25-NB: 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe Amphetamines: 3C-Scalines: TMA (3,4,5-TMA) DOx: 2,5-DMA, DOM, DOET, DOB MDxx: MDA, MDOH (N-hydroxy-MDA), MMDA, MDMA, MDEA Methoxyamphetamines: PMA and PMMA Cyclized phenethylamines: 3-Benzazepines: lorcaserin Lysergamides: ergine (LSA) and LSD Arylpiperazines: benzylpiperazine (BZP) The arylpiperazine TFMPP was temporarily scheduled in 2002, but this expired in 2004 and was not renewed. The amphetamine fenfluramine was also previously a controlled substance, but was unscheduled in 2022. Certain synthetic precursors, including phenylacetone (P2P) and lysergic acid, among others, are controlled substances as well. Other regulated precursors include safrole, piperonal, MDP2P, ergocristine, ergonovine (ergometrine), and ergotamine, among others. Although not technically a serotonergic psychedelic, the oneirogen ibogaine, a constituent of Tabernanthe iboga and a compound structurally related to tryptamine psychedelics, is also an explicitly controlled substance in the United States.
Many variations of condensation reactions exist. Common examples include the aldol condensation and the Knoevenagel condensation, which both form water as a by-product, as well as the Claisen condensation and the Dieckman condensation (intramolecular Claisen condensation), which form alcohols as by-products.
Later that year, tapentadol was approved in Europe. In 2011, Nucynta ER, an extended release formulation of tapentadol, was released in the United States for management of moderate to severe chronic pain and received Food and Drug Administration approval the following year for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. After annual sales of $166 million, in January 2015, Johnson & Johnson sold its rights to market tapentadol in the US to Depomed for $1 billion. The drug was manufactured at a plant located on the island of Puerto Rico that was hit by Hurricane Maria in 2017 causing a major shortage in the drug's availability. In January 2018 Depomed sold off the manufacturing of the drug and licensed it to Collegium Pharmaceutical for $10 million up front with an annual royalty payment of a minimum $135 million for the next 4 years. This combination of events has caused additional short supply of the drug leaving patients who depend on it to seek alternative treatments.
== Processing == Designing food for consumption in space is an often difficult process. Foods must meet a number of criteria to be considered fit for space. Food must be physiologically appropriate, in that it must be nutritious, easily digestible, and palatable. Secondly, the food must be engineered for consumption in a zero-gravity environment. As such, the food must be light, well packaged, fast to serve, and require minimal cleaning up. Finally, foods require a minimum of energy expenditure throughout their use; they must store well, open easily, and leave little waste behind (foods that tend to leave crumbs, for example, are ill-suited for space). Carbonated drinks have been tried in space but are not favored due to changes in belching caused by microgravity. Without gravity to separate the liquid and gas in the stomach, burping results in a kind of vomiting called "wet burping". Coca-Cola and Pepsi were first carried on STS-51-F in 1985. Coca-Cola has flown on subsequent missions in a specially designed dispenser that utilizes BioServe Space Technologies hardware used for biochemical experiments. Space Station Mir carried cans of Pepsi in 1996.
Sources: en.wikipedia.org
=== Abnormality battles === Players can fight in Abnormality battles, boosting the respective floor's realization level and power. Many of the Abnormalities present in-game originate from the prequel, Lobotomy Corporation. Every Abnormality battle has a certain gimmick or mechanic the player must figure out to defeat them. After completing an Abnormality battle, a new librarian will be unlocked for the floor. Including the Patron Librarian, five librarians in total will be available per floor. Players can customize a librarian's name, appearance, and combat dialogue. Completing Abnormality battles also grants Abnormality pages used in battles. The Abnormality pages can be split into two categories: Awakening and Breakdown. The Awakening Abnormality cards are the green ones and provide a small benefit with no downsides. The Breakdown Abnormality cards are red, with both a strong benefit and a downside. The severity of the downside depends on the card itself.
=== Occupational therapy === Occupational therapy—often abbreviated OT—is the "use of productive or creative activity in the treatment or rehabilitation of physically, cognitively, or emotionally disabled people." Most commonly, occupational therapists work with people with disabilities to enable them to maximize their skills and abilities. Occupational therapy practitioners are skilled professionals whose education includes the study of human growth and development with specific emphasis on the physical, emotional, psychological, sociocultural, cognitive and environmental components of illness and injury. They commonly work alongside clinical psychologists in settings such as inpatient and outpatient mental health, pain management clinics, eating disorder clinics, and child development services. OT's use support groups, individual counseling sessions, and activity-based approaches to address psychiatric symptoms and maximize functioning in life activities.
=== Molecular electronics applications === Molecular 'switch' peptides can be made into nanoswitches when an electronic component is incorporated. Metal nanocrystals can be covalently linked to the peptides to make them electronically responsive; research is currently being conducted on how to develop electronically controlled molecules and molecular 'machines' using such molecular 'switches'. Peptide nanofibers can also be used as growth templates for a range of inorganic materials, such as silver, gold, platinum, cobalt, nickel, and various semiconducting materials. Electrons transferring aromatic moieties can also be attached to the side chains of peptides to form conducting nanostructures that can transfer electrons in a certain direction. Metal and semiconductor binding peptides have been used for the fabrication of nanowires. Peptides self-assemble into hollow nanotubes to act as casting molds; metal ions that migrate inside the tube undergo reduction to metallic form. The peptide 'mold' can then be enzymatically destroyed to produce a metal nanowire of about 20 nm diameter. This has been done making gold nanowires and this application is especially significant because nanowires at this scale cannot be made by lithography. Researchers have also successfully developed multi-layer nanocables with a silver core nanowire, a peptide insulation layer, and a gold outer coat. This is done by reducing AgNO3 inside nanotubes, and then bounding a layer of thiol-containing peptides with gold particles attached.
=== Tricyclic antidepressants === Tricyclic antidepressants (TCAs) have anxiolytic effects; however, side effects are often more troubling or severe and overdose is dangerous. They are considered effective, but have generally been replaced by antidepressants that cause different adverse effects. Examples include imipramine, doxepin, amitriptyline, nortriptyline and desipramine.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.